[Skip to Navigation]
Sign In
May 30, 2019

Tumor Mutation Burden—From Hopes to Doubts

Author Affiliations
  • 1Oncology Department, Geneva University Hospital, Geneva, Switzerland
  • 2Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy
  • 3Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
JAMA Oncol. 2019;5(7):934-935. doi:10.1001/jamaoncol.2019.0626

Over the past few years, the development of immune checkpoint inhibitors has altered the treatment paradigm in non–small cell lung cancer (NSCLC). Enrichment strategies have identified programmed death-ligand 1 (PD-L1) staining by immunohistochemistry to be a predictive biomarker in treatment-naive patients with refractory NSCLC. In particular, Keynote-0241 met its primary end points for overall survival (OS) and progression-free survival (PFS) in PD-L1 immunohistochemistry 50% or greater for pembrolizumab compared with platinum-based chemotherapy, validating PD-L1 immunohistochemistry as a biomarker for OS. Tumor mutation burden (TMB) has also emerged as a possible biomarker. The prevalence of somatic mutations among cancers ranges from 0.01 mutations/megabase (Mb) to more than 400 mutations/Mb. Some of these mutations lead to the translation of novel peptide epitopes or neoantigens that should enhance the immunogenicity of the tumor by eliciting T-cell repertoires. Initial studies of TMB were conducted by using whole-exome sequencing on tumor DNA and case-matched germline DNA.

Add or change institution